Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialResearch in context

Summary: Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2−/PIK3CA-mutated advanced breast cancer (ABC). Methods: Between August 13...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	EClinicalMedicine
المؤلفون الرئيسيون:	Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2024-05-01
الموضوعات:	Alpelisib Hyperglycaemia Prophylactic metformin HR+/HER2−/PIK3CA-mutated advanced breast cancer
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2589537024000993